ExpreS2ion’s rights issue oversubscribed
Hørsholm, Denmark, March 2nd, 2018 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that the Company’s rights issue of approximately SEK 19.2 million in order to finance investments in several parts of the core business and also to supply additional working capital for future investments in new business opportunities for both ExpreS2ion and AdaptVac, has been oversubscribed. The rights issue was subscribed to approximately SEK 30.3 million, corresponding to a subscription rate of approximately 158 percent. Through the rights issue, a total of 2,400,403 shares are issued and